Mandate

Vinge advised Fortum Värme in connection with the Swedish Competition Authority’s three-year investigation regarding the price of district heating in Stockholm

November 15, 2010

Since October 2007 the Swedish Competition Authority has investigated whether Fortum Värme, jointly owned by Fortum and the City of Stockholm, abused a dominant position in breach of the Swedish Competition Act by imposing unfairly high prices (excessive pricing) on its district heating customers in the Stockholm area. The Competition Authority has, by its unconditional decision on 12 November 2010, now closed the extensive and detailed investigation without any further actions. Fortum Värme has, during the investigation, declared its intention to ensure, for 2011, that the revenues generated from its district heating operations in Stockholm do not exceed a revenue cap defined by the company.     

Vinge’s competition team included responsible partner Johan Karlsson and several associates, including Carl Johan Sundqvist and Emil Fahlén Godö. Part of the team was also associate professor Mattias Ganslandt who, inter alia, contributed with several economic reports concerning the market for district heating and Fortum Värme’s pricing.

The Swedish Competition Authority’s decision and press release

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026